A missing link between RON expression and oncological outcomes in resected left-sided pancreatic cancer

Dai Hoon Han, ChangMoo Kang, Sung Whan Lee, Ho Kyoung Hwang, Woo Jung Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Alteration and activation of recepteur d'origine nantais (RON) expression is known to be associated with cancer progression and decreased survival in various types of human cancer, including pancreatic cancer. Therefore, in the present study, RON expression levels were determined in resected left-sided pancreatic cancer to evaluate the potential oncological role of RON in the clinical setting of distal pancreatic cancer. From January 2005 to December 2011, a total of 57 patients underwent radical distal pancreatectomy for left-sided pancreatic cancer. Ductal adenocarcinoma was confirmed in all patients. Among these patients, 17 patients who received preoperative neoadjuvant treatment and 7 patients without available paraffin-embedded tissue blocks were excluded from the present study. RON expression in a the pancreatic cancer cell lines ASPC-1, BxPC-3, MiaPaCa-3 and Panc-1, as well as in resected left-sided pancreatic cancer specimens was determined by Western blot analysis. RON and vascular endothelial growth factor (VEGF) overexpression in resected left-sided pancreatic cancer was also evaluated by immunohistochemistry using pre-diluted anti-RON and anti-VEGF antibodies. An association was identified between the oncological outcome and RON overexpression. Increased levels of RON expression were observed in two pancreatic cancer cell lines, AsPC-1 and BxPC-3. RON overexpression was detected in specimens from 15/33 patients (45.5%) using immunohistochemistry. No significant association was identified between RON overexpression and VEGF overexpression (25.5 vs. 87.9%; P=0.667). No significant differences in disease-free survival or disease-specific survival associated with RON overexpression were identified. Although the results of previous studies have suggested that RON is a potential target for the treatment of pancreatic cancer, in the present study no association between RON overexpression and any adverse oncological effect was identified.

Original languageEnglish
Pages (from-to)4225-4230
Number of pages6
JournalOncology Letters
Volume14
Issue number4
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Pancreatic Neoplasms
Vascular Endothelial Growth Factor A
RON protein
Immunohistochemistry
Cell Line
Pancreatectomy
Neoadjuvant Therapy
Survival
Paraffin
Disease-Free Survival
Neoplasms
Adenocarcinoma
Western Blotting

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Han, Dai Hoon ; Kang, ChangMoo ; Lee, Sung Whan ; Hwang, Ho Kyoung ; Lee, Woo Jung. / A missing link between RON expression and oncological outcomes in resected left-sided pancreatic cancer. In: Oncology Letters. 2017 ; Vol. 14, No. 4. pp. 4225-4230.
@article{9f95a145109945beb765271999f583b1,
title = "A missing link between RON expression and oncological outcomes in resected left-sided pancreatic cancer",
abstract = "Alteration and activation of recepteur d'origine nantais (RON) expression is known to be associated with cancer progression and decreased survival in various types of human cancer, including pancreatic cancer. Therefore, in the present study, RON expression levels were determined in resected left-sided pancreatic cancer to evaluate the potential oncological role of RON in the clinical setting of distal pancreatic cancer. From January 2005 to December 2011, a total of 57 patients underwent radical distal pancreatectomy for left-sided pancreatic cancer. Ductal adenocarcinoma was confirmed in all patients. Among these patients, 17 patients who received preoperative neoadjuvant treatment and 7 patients without available paraffin-embedded tissue blocks were excluded from the present study. RON expression in a the pancreatic cancer cell lines ASPC-1, BxPC-3, MiaPaCa-3 and Panc-1, as well as in resected left-sided pancreatic cancer specimens was determined by Western blot analysis. RON and vascular endothelial growth factor (VEGF) overexpression in resected left-sided pancreatic cancer was also evaluated by immunohistochemistry using pre-diluted anti-RON and anti-VEGF antibodies. An association was identified between the oncological outcome and RON overexpression. Increased levels of RON expression were observed in two pancreatic cancer cell lines, AsPC-1 and BxPC-3. RON overexpression was detected in specimens from 15/33 patients (45.5{\%}) using immunohistochemistry. No significant association was identified between RON overexpression and VEGF overexpression (25.5 vs. 87.9{\%}; P=0.667). No significant differences in disease-free survival or disease-specific survival associated with RON overexpression were identified. Although the results of previous studies have suggested that RON is a potential target for the treatment of pancreatic cancer, in the present study no association between RON overexpression and any adverse oncological effect was identified.",
author = "Han, {Dai Hoon} and ChangMoo Kang and Lee, {Sung Whan} and Hwang, {Ho Kyoung} and Lee, {Woo Jung}",
year = "2017",
month = "1",
day = "1",
doi = "10.3892/ol.2017.6696",
language = "English",
volume = "14",
pages = "4225--4230",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "4",

}

A missing link between RON expression and oncological outcomes in resected left-sided pancreatic cancer. / Han, Dai Hoon; Kang, ChangMoo; Lee, Sung Whan; Hwang, Ho Kyoung; Lee, Woo Jung.

In: Oncology Letters, Vol. 14, No. 4, 01.01.2017, p. 4225-4230.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A missing link between RON expression and oncological outcomes in resected left-sided pancreatic cancer

AU - Han, Dai Hoon

AU - Kang, ChangMoo

AU - Lee, Sung Whan

AU - Hwang, Ho Kyoung

AU - Lee, Woo Jung

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Alteration and activation of recepteur d'origine nantais (RON) expression is known to be associated with cancer progression and decreased survival in various types of human cancer, including pancreatic cancer. Therefore, in the present study, RON expression levels were determined in resected left-sided pancreatic cancer to evaluate the potential oncological role of RON in the clinical setting of distal pancreatic cancer. From January 2005 to December 2011, a total of 57 patients underwent radical distal pancreatectomy for left-sided pancreatic cancer. Ductal adenocarcinoma was confirmed in all patients. Among these patients, 17 patients who received preoperative neoadjuvant treatment and 7 patients without available paraffin-embedded tissue blocks were excluded from the present study. RON expression in a the pancreatic cancer cell lines ASPC-1, BxPC-3, MiaPaCa-3 and Panc-1, as well as in resected left-sided pancreatic cancer specimens was determined by Western blot analysis. RON and vascular endothelial growth factor (VEGF) overexpression in resected left-sided pancreatic cancer was also evaluated by immunohistochemistry using pre-diluted anti-RON and anti-VEGF antibodies. An association was identified between the oncological outcome and RON overexpression. Increased levels of RON expression were observed in two pancreatic cancer cell lines, AsPC-1 and BxPC-3. RON overexpression was detected in specimens from 15/33 patients (45.5%) using immunohistochemistry. No significant association was identified between RON overexpression and VEGF overexpression (25.5 vs. 87.9%; P=0.667). No significant differences in disease-free survival or disease-specific survival associated with RON overexpression were identified. Although the results of previous studies have suggested that RON is a potential target for the treatment of pancreatic cancer, in the present study no association between RON overexpression and any adverse oncological effect was identified.

AB - Alteration and activation of recepteur d'origine nantais (RON) expression is known to be associated with cancer progression and decreased survival in various types of human cancer, including pancreatic cancer. Therefore, in the present study, RON expression levels were determined in resected left-sided pancreatic cancer to evaluate the potential oncological role of RON in the clinical setting of distal pancreatic cancer. From January 2005 to December 2011, a total of 57 patients underwent radical distal pancreatectomy for left-sided pancreatic cancer. Ductal adenocarcinoma was confirmed in all patients. Among these patients, 17 patients who received preoperative neoadjuvant treatment and 7 patients without available paraffin-embedded tissue blocks were excluded from the present study. RON expression in a the pancreatic cancer cell lines ASPC-1, BxPC-3, MiaPaCa-3 and Panc-1, as well as in resected left-sided pancreatic cancer specimens was determined by Western blot analysis. RON and vascular endothelial growth factor (VEGF) overexpression in resected left-sided pancreatic cancer was also evaluated by immunohistochemistry using pre-diluted anti-RON and anti-VEGF antibodies. An association was identified between the oncological outcome and RON overexpression. Increased levels of RON expression were observed in two pancreatic cancer cell lines, AsPC-1 and BxPC-3. RON overexpression was detected in specimens from 15/33 patients (45.5%) using immunohistochemistry. No significant association was identified between RON overexpression and VEGF overexpression (25.5 vs. 87.9%; P=0.667). No significant differences in disease-free survival or disease-specific survival associated with RON overexpression were identified. Although the results of previous studies have suggested that RON is a potential target for the treatment of pancreatic cancer, in the present study no association between RON overexpression and any adverse oncological effect was identified.

UR - http://www.scopus.com/inward/record.url?scp=85028943375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028943375&partnerID=8YFLogxK

U2 - 10.3892/ol.2017.6696

DO - 10.3892/ol.2017.6696

M3 - Article

AN - SCOPUS:85028943375

VL - 14

SP - 4225

EP - 4230

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 4

ER -